Ann: Kazia Corporate Presentation, page-37

deal making is specifically our forte hence 400 million in deals last month! and now an in license so very cheaply.

it’s the Kazia super power if there is one thing to point to.

and we need to license our products that’s the business model... there’s no stasis there’s only growth or death - the Pax licensing deal was effectively 350 million in milestones for less than 10% of the market - it’s the best licensing deal there is and values the other 90% clearly

even the analysts are saying it’s incredible an A+ deal - it’s also unheard of for a asx biotech to do two lic deals across two products in one month.

we are on track making all the right moves and it is because this management team is the best in the business... bar none. They are well connected and well trusted as a partner very capable and clearly able to sell that into partners.

we watched partnership after partnership open up with pax and it’s the current driving force obviously but looking back in five short years we have entered a phase 3 pivotal study from dose discovery and MTD phase 1 1B - these guys are achieving phase in a couple short years based on Paxalisib.

- and if EVT901 is just as interesting to our management and science team as they have clearly said it is, then theres no reason why we can’t follow a similar path and timeline - if anything it should be quicker and easier as we have working frameworks in place to handle these specific process’ moving in and around clinic...

agile process’ are structural and not dependent on drug or cohort and we have seen the benefits in pulling pax into GBM agile super quickly with a control arm already running for over a year

this will be the same.

as James said on the call this morning - having pax and evt801 offers a greater redundancy in terms of company risk... the more products you have the less risk and reliance in any single compound - but this isn’t to mitigate risk with pax - pax has provided us with the opportunity to do more and a natural outcome is derisking

it’s clear we are uniquely positioned (and with a growing reputation) to pull in interesting compounds - I don’t think it’s lost on anyone that this new drug is similar to pax in that it is dedicated to treating multiple conditions through attacking a common cancer cell growth pathway they share... lung, liver and kidney it’s a very nice addition to brain cancers.

Kazia is becoming a much bigger beast with much greater potential across a larger pipeline.